Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7621 to 7635 of 8323 results

  1. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued

  2. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued Reference number: GID-TAG413

    Technology appraisal guidance
    Discontinued

  3. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued Reference number: GID-TAG414

    Technology appraisal guidance
    Discontinued

  4. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued Reference number: GID-TAG415

    Technology appraisal guidance
    Discontinued

  5. Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

    Discontinued Reference number: GID-TAG416

    Technology appraisal guidance
    Discontinued

  6. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued Reference number: GID-TAG417

    Technology appraisal guidance
    Discontinued

  7. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    Discontinued Reference number: GID-TA11108

    Technology appraisal guidance
    Discontinued

  8. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    Discontinued Reference number: GID-TA10965

    Technology appraisal guidance
    Discontinued

  9. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued Reference number: GID-TA10863

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    Discontinued Reference number: GID-TA10766

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued Reference number: GID-TA11004

    Technology appraisal guidance
    Discontinued

  12. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued Reference number: GID-TA11244

    Technology appraisal guidance
    Discontinued

  13. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued Reference number: GID-TA10185

    Technology appraisal guidance
    Discontinued

  14. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued Reference number: GID-TA11255

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

    Discontinued Reference number: GID-TA10848

    Technology appraisal guidance
    Discontinued